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1. Introduction
High-resolution volumetric optical imaging modalities, such as confocal microscopy, two-
photon microscopy, and optical coherence tomography, have become increasingly important
in the biomedical imaging field. However, due to strong light scattering, the penetration depths
of these imaging modalities are limited to the optical transport mean free path in biological
tissues, e.g., ~1 mm in the skin. Photoacoustic tomography (PAT), an emerging hybrid imaging
modality that can provide strong endogenous and exogenous optical absorption contrasts with
high ultrasonic spatial resolution using the photoacoustic (PA) effect,1 has overcome the
fundamental depth limitation. The image resolution is scalable with the ultrasonic frequency.
The imaging depth is limited to the reach of photons and up to a few centimeters deep in
biological tissues. This article will review the following aspects of PAT described in works
published from 2003 to 2009: (1) multi-scale PAT systems, (2) morphological and functional
PAT using intrinsic contrasts (hemoglobin or melanin), and (3) functional and molecular PAT
using exogenous contrast agents (organic dyes, nanoparticles, reporter genes, or fluorescence
proteins).
Figure 1 illustrates the PA effect and its application to imaging. In general, a target is irradiated
by a short-pulsed laser beam. A portion of the light is absorbed by the target’s constituents and
then partially converted into heat, which generates a pressure rise through thermo-elastic
expansion. This initial pressure rise—determined by the local optical energy deposition and
other thermal and mechanical properties—is propagated as an acoustic wave in the biological
tissue and detected by ultrasonic transducers. PA images are derived from the arrival times of
the ultrasonic waves. PAT image contrast is determined by optical absorption in the PA
excitation phase, whereas its resolution is derived from ultrasonic detection in the PA emission
phase. The combination of these intrinsic properties enable PA imaging to break through the
fundamental limitations of pure optical imaging2–5 (i.e., shallow imaging depth for high
resolution or low spatial resolution beyond the transport mean free path) and pure ultrasonic
imaging (i.e., weak contrast for early cancer detection and speckle artifacts). By scaling the
ultrasonic detection frequency, the spatial resolution and imaging depth can be tuned
accordingly to the imaging application.
There are two major types of PAT systems. One is photoacoustic computed tomography
(PACT), which uses reconstruction algorithms to generate an image.6 The second is
photoacoustic microscopy (PAM) or macroscopy, which utilizes direct point by point detection
and raster scanning over an object to render an image. PACT can be implemented using a
single-element unfocused ultrasound transducer and circular scanning,6 or an ultrasound array
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system in circular7, quarter-circular8, or linear form. The imaging speed is dramatically
improved in the latter approach and is ultimately limited to the pulse repetition rate of the
excitation light source and the tissue damage threshold. By contrast, PAM does not require the
use of an inverse algorithm to generate a three-dimensional image, but it requires raster
scanning with a single-element focused transducer. An example of a PAM system is a dark-
field confocal photoacoustic microscope9,10 Based on recently reported experimental results,
PAM imaging depth is scalable from 0.7 to 30 mm by varying the ultrasonic frequency from
75 to 3.5 MHz,10–12 whereas the spatial resolution is scalable from 5 to 150 µm.
Purely with endogenous contrasts such as hemoglobin or melanin, PAT is able to produce high
resolution images of vascular structures,9,12 solid tumors and angiogenesis,9,13 and internal
organs11,14 in vivo. In addition to morphological information, this technique can provide
functional information such as oxygen saturation of hemoglobin and total hemoglobin
concentration, using multiple wavelengths of light.6,9,15,16 Important to many functional
measurements is the acquisition speed. With ultrasound array systems, PA imaging is
sufficiently fast and capable of monitoring real-time heart beats in small animals.17 Exogenous
contrast agents (organic dyes, nanoparticles, reporter genes, or fluorescence proteins) with
biomarkers further enhances PA imaging, making it an increasingly valuable tool for molecular
imaging.18,19
2. Photoacoustic tomography systems
2.1. Photoacoustic computed tomography (PACT)
2.1.1. A single-element unfocused ultrasound transducer based PACT—When
the laser pulse width is shorter than the characteristic thermal diffusion time (referred to as
thermal confinement), PA waves p(r0, t) are related to light absorption H(r, t) as follows: 20
(1)
where vs is the acoustic velocity, CP is the specific heat, and β is the volumetric thermal
expansion coefficient. In addition, the light absorption H(r, t) is equal to Ae(r)I(t), where
Ae(r) denotes the spatial distribution of optical energy deposition, F(r)µa(r), and I(t) denotes
the temporal laser pulse profile, where F(r) denotes the local fluence and µa(r) denotes the
local optical absorption coefficient.
If I(t) is a Dirac delta function, a PA wave received at a detection point r0 (Figure 2) can be
described as follows:21
(2)
where ds is the surface element of a unit sphere and R is |r – r0|.
By assuming the detection point r0 is far from the source point at r compared to the wavelength
of PA wave, the spatial map of optical energy deposition Ae(r) can be reconstructed as follows:
20
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(3)
where Ω0 is the solid angle of the whole detection surface with respect to a given point source
and dΩ is the solid angle of a detection element. If the fluence in the imaging plane is
homogeneous at a given optical wavelength, the image of Ae(r) is proportional to the image of
µa(r); otherwise, fluence F(r) need to be considered for quantitative analysis of µa(r).
As an example, a schematic of a PACT system with a circularly scanning, single-element
unfocused ultrasonic transducer used for small-animal brain imaging is shown in Figure 3.15
The system employed a tunable dye laser (ND6000, Continuum) pumped by an Nd:YAG laser
(Brilliant B, Big Sky) to generate laser pulses with a pulse duration of 6.5 ns at 10 Hz. The
laser beam was first expanded using a concave lens and homogenized using a ground glass.
The incident energy density on skin surface was less than 3 mJ/cm2, which is well below the
ANSI standard of 20 mJ/cm2.22 An unfocused ultrasonic transducer (e.g., XMS-310 or V383,
Panametrics) was circularly scanned around the rat brain cortex in the horizontal (x-y) plane.
By incrementally moving the ultrasonic transducer along the z-direction, volumetric
information was obtained. The detected PA signals were first amplified and then digitized by
an oscilloscope. Finally, 3D PA images were reconstructed and displayed in the computer.
Since this system requires mechanical scanning of a single-element transducer, the scanning
times required for both 2D and 3D images were approximately 15 minutes and several hours,
respectively.
The PACT imaging was performed on an adult Sprague Dawley rat (~350 g) using a 10-MHz
ultrasonic transducer. The images were obtained noninvasively with the scalp and skull intact.
Figure 4 shows the transdermal and transcranial images of a rat’s brain acquired in vivo. The
optical absorption is indicated with a gray scale, where the darker areas—such as blood vessels
—have relatively higher absorption. The PA image of the rat brain cortex (Figure 4A) matches
well with the open-skull photograph (Figure 4B) obtained after PA imaging.
2.1.2. A ring ultrasound array based real-time PACT7,8—As mentioned above, single-
element based PACT systems can be relatively slow and the example system required about
15 minutes to collect single 2D tomographic image. However, by employing a full-ring
transducer array, the temporal resolution can be significantly improved. The system described
below utilizes a 512 element full-ring transducer array and can collect one 2D tomographic
image at the frame rate of 0.9 Hz.
A schematic of 512-element, 360-degree PACT system is shown in Figure 5. A Ti:Sapphire
(Symphotics TII, LS-2134) laser pumped by a Q-switched Nd:YAG laser (Symphotics-TII,
LS-2122) illuminated a small-animal brain with 8–12 ns pulses. The laser beam was first
expanded and homogenized before striking the target. The custom-made transducer array
(Imasonic) consisted of 512 elements in a curved aperture such that a complete circle (i.e., 360
degrees) was formed with a radius of 25 mm. The center frequency of the transducers in this
array system was 5 MHz with a nominal bandwidth greater than 80%. The system was also
equipped with 512 dedicated low-noise and 20 dB gain preamplifiers. With 8:1 multiplexing,
eight laser pulses were necessary to generate a complete 512-element capture. Data setup and
transfer of results for a single acquisition could be performed at a frequency up to 8 Hz, leading
to a maximum full-capture rate of about 1 frame/second.
The brain cortex of a mouse (~ 20 g) was noninvasively imaged to demonstrate the potential
of dynamic spectroscopic PA imaging to monitor regional and temporal changes in
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oxygenation status throughout a small-animal brain. During the 30-second imaging
experiment, the laser wavelength of the laser was manually tuned from approximately 700 nm
to 900 nm. Figure 6 shows the individual frames from the real-time sequence. The vascular
structures of the brain cortex are clearly visible. The higher PA signals in blood vessels at 850
nm can be explained by both an increased penetration depth due to less optical scattering and
higher absorption coefficients of the predominantly oxygenated hemoglobin at longer
wavelengths. This experiment demonstrated the capability to perform wide-range, in vivo
spectroscopic studies with sub-minute scan times.
2.1.3. A linear ultrasound array based real-time PACT17,23,24—Linear transducer
arrays can also be used for PACT. A high-frequency (30 MHz) linear ultrasound transducer
array was adapted to create a microscopic PACT system. This system performs real-time depth-
resolvable 2D imaging (referred to as B-scan) at 50 Hz (faster than the 30-Hz video rate) with
real-time beamforming and 3D imaging of 166 B-scan frames at 1 Hz post beamforming.
The schematic of microscopic PACT system is depicted in Figure 7. The tunable dye laser
(Cobra, Sirah) pumped by a Nd:YLF laser (INNOSLAB, Edgewave) produced 7-ns laser pulses
at the maximum repetition rate of 1 kHz without compromising the pulse energy. Dark-field
confocal light delivery configuration was designed to provide a compact system with sufficient
signal-to-noise ratio (SNR) and robust performance. The laser pulses were coupled into a
multimode fiber and collimated at the exit of the fiber. The collimated beam was split into two
beams by a 50:50 nonpolarizing beamsplitter. The two beams were reflected by mirrors toward
two cylindrical lenses and coupled into a plastic slab. The optical fluence on the skin surface
was ~2 mJ/cm2 per pulse, well within the ANSI safety limit.22 A 30-MHz linear ultrasound
transducer array was fabricated by a 2-2-piezocomposite and was comprised of 48 elements
(82 µm × 2 mm) with 100-µm spacing. The dimension of the element in the elevation direction
was 2 mm, and the elements were focused in this direction with a fixed focal length of 8.2 mm.
The axial, lateral, and elevational resolutions at 7-mm depth from the transducer surface were
estimated to be 25, 70, and 200 µm, respectively. The imaging depth in biological tissues was
deeper than 3 mm. The detected PA signals were first amplified and then multiplexed to eight
channels. Linear scanning was performed to achieve 3-D imaging.
To demonstrate this system’s capability to image blood vessels in vivo, the upper dorsal region
of a Sprague Dawley rat (~95 g) was imaged. Figure 8 shows an in vivo PA image and an ex
vivo transmission optical microscopic image of the subcutaneous vasculature in an imaged
area. As shown in Figure 8, the vascular distributions in the two images matched well. The
data acquisition for this image was completed within 1 s, and the MAP image was displayed
within 3–4 s.
2.2. Confocal photoacoustic microscopy (PAM)
2.2.1. A single-element focused ultrasound transducer based dark-field
confocal PAM9,10,25—As opposed to PACT, dark-field confocal PAM utilizes a spherically
focused ultrasound transducer. The axial resolution of this type of PAM is determined by the
bandwidth of the transducer and the transverse resolution is limited to the numerical aperture
of the spherically focused acoustic lens. By measuring the time of arrivals of the PA signals,
one dimensional depth resolved image can be obtained, referred to as an A-line. Raster scanning
along the two transverse directions enables to form three-dimensional images of optical
absorption heterogeneities in biological tissues. Consequently, no additional reconstruction
algorithm is required in PAM. The acquired volumetric images were expressed in one of two
forms: a maximum amplitude projection (MAP), in which the maximum signal from each A-
line is projected onto the corresponding XY plane or a true volumetric image processed by
Volview software (Kitware Inc.).
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A dark-field confocal PAM system is shown in Figure 9. The light was delivered from a tunable
dye laser (ND6000, Continuum) pumped by a Q-switched Nd:YAG laser (LS-2137, LOTIS)
with 6-ns pulse duration and 10-Hz pulse repetition rate. A multimode fiber was used for the
light delivery. A dark-field illumination pattern was formed by the combination of a spherical
conical lens and a weakly focusing optical condenser and was coaxially aligned with the
ultrasound focus in water. This dark-field confocal configuration provides a greater penetration
depth and higher SNR than the previously discussed confocal PACT systm.26 The light fluence
on the skin was less than 6.4 mJ/cm2, which is within the ANSI limit.22 Generated PA waves
were detected by a single-element ultrasound transducer (20 or 50 MHz). The 50-MHz
ultrasonic frequency yielded 15 µm and 45 µm axial and transverse resolutions, respectively.
The maximum penetration depth at 50 MHz was about 3 mm. As mentioned in the Introduction
section, the spatial resolution and imaging depth are highly scalable as a function of the
ultrasonic frequency.
By taking advantage of the high optical absorption in hemoglobin and melanin, subcutaneous
microvaculatures and melanoma in mice were imaged using the PAM system in vivo. Figure
10A shows a composite image of a melanoma and surrounding vascular structures. These dual
pigments were imaged with two different wavelengths, 584 nm for the surrounding
microvasculature and 764 nm for the melanoma. The bottom panel in Figure 10A shows the
corresponding two dimensional depth-resolved image (referred to as B-scan) along the dashed
line in the top panel. The averaged image contrast of blood vessels at 584 nm compared to
background is 13 ± 0.89, and that of the melanoma at 764 nm is 68 ± 5. Figure 10B shows the
mouse brain cortical microvasculature imaged using 20 MHz ultrasonic frequency and 570 nm
optical wavelength.27 Major vascular landmarks (sagittal sinus, middle cerebral artery, and
coronal suture) are clearly identified. The corresponding bottom figure shows the B-scan image
along the dashed line in the top figure.
2.2.2. Deep-reflection mode PA macroscopy 11,14—To test the imaging capability in
deep tissues and demonstrate the scalability of PAM, the deep-reflection mode PAM system
was constructed and tested. The imaging penetration depth was increased more than 3 cm by
lowering the ultrasonic frequencies to 3.5 – 10 MHz. For example, using a 5 MHz ultrasonic
frequency the spatial resolutions at 19 mm deep in biological tissue were 144 µm in the axial
direction and 560 µm in the transverse direction. The principle of this system is the same as
the previously described dark-field confocal PAM system15, but the system has been scaled
for deep imaging. Figure 11 shows the images of several internal organs such as a liver, a
kidney, and an intestine from small and large animals imaged in situ. A Sprague Dawley rat
weighing ~ 200 g and a New Zealand white rabbit weighing ~ 3 kg were used for the small
and large animal imaging, respectively. The liver and kidney of the rat are clearly identified
in Figure 11A and 11B, respectively. The intestine of the rabbit is also clearly shown in Figure
11C, and match well with the photograph (Figure 11D) taken after the PA imaging.
2.2.3. Optical-resolution PAM (OR-PAM)12—Thus far, both axial and transverse
resolutions in the above mentioned PAM systems depend solely on ultrasonic parameters. To
improve the ultrasonic resolution to the order of a µm, the penetration depth, which is limited
by the frequency-dependent ultrasonic attenuation in tissues, becomes severely reduced. For
example, to achieve a 5 µm transverse resolution, a 300 MHz of ultrasonic frequency is
required. Consequently, the penetration depth is limited to ~ 100 µm in tissue due to the strong
acoustic attenuation. As an alternative approach, optical focusing can provide fine transverse
resolution while the axial resolution is still derived from the ultrasonic bandwidth. This
technique is referred as optical-resolution photoacoustic microscopy (OR-PAM). Although in
this case the imaging depth is limited to the ballistic photon regime due to strong light scattering
like other pure optical microscopy techniques, 2–4 OR-PAM can still probe deeper than a PA
system with the same transverse resolution provided by ultrasonic focusing. OR-PAM provides
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primarily optical absorption contrast, whereas conventional optical microscopy provides
dominantly optical scattering or fluorescence contrast.
The experimental schematic of an OR-PAM system is shown in Figure 12. A dye laser pumped
by a Nd:YLF laser was used as the PA excitation source. Laser pulses (pulse duration, 7 ns)
passing through a 25-µm-diameter pinhole were spatially filtered, and then the pinhole was
imaged to a nearly diffraction-limited focal spot with 3.7 µm in diameter through an objective
lens (NA, 0.1; depth of focus, ~40 µm). About 100 nJ of the pulse energy after the objective
lens was used. The ultrasound transducer (V2022 BC, Olympus NDT, 75 MHz) was focused
through a plano-concave lens (radius of curvature, 5.2 mm; aperture, 6.4 mm; NA in water,
0.46). Therefore, both optical illumination and acoustic detection were coaxially aligned. A
3D image was acquired by raster scanning the surface of the target and combining the 1D depth
scans received at each surface position. The transverse and axial resolutions of this system
were 5 and 15 µm, respectively, and the maximum penetration depth was better than 700 µm.
Microvasculature in the ear of a nude mouse (~ 20 g) was imaged in vivo at an optical
wavelength of 578 nm. Unlike that in the ref 28, no optical clearing agent was applied to the
skin surface. The microvasculature is clearly seen in two-dimensional MAP (Figure 13A) and
volumetric OR-PAM images (Figure 11B), which agree well with the photograph (Figure 11C)
taken with a transmission optical microscope. Small sizes of blood vessels are only observable
in the OR-PAM image. The image contrast of blood vessels is nearly 20, compared to the
background. Some vessels labeled with CL show a diameter of ~5 µm, comparable to the
diameter of a single capillary. These results demonstrate the capability of OR-PAM to image
single capillaries in vivo without additional exogenous contrast agents.
3. Functional photoacoustic tomography using intrinsic contrasts
3.1. Functional imaging of blood vessels in vivo using PAT29
Functional, biological images, such as the total hemoglobin concentration (HbT) and
hemoglobin oxygen saturation (SO2), are important in many medical and biomedical fields.
These measurements are valuable for imaging brain activation,30 studying tumor
physiopathology,31 monitoring wound healing process,32 and studying gene expression.33
Currently, the following other techniques can potentially estimate SO2:
1. Near-Infrared Spectroscopy (NIRS)34: NIRS measures reflected or transmitted
diffusive light from biological tissues at various optical wavelengths and estimates
the SO2 comparing optical-spectral differences between deoxy-hemoglobin (HbR)
and oxy-hemoglobin (HbO2). However, it is difficult to collect localized
measurements due to strong light scattering in biological tissues.
2. Blood-Oxygen-Level-Dependent contrast Magnetic Resonance Imaging (BOLD
MRI)35: Despite the high spatial resolution of BOLD MRI, the contrast is only
sensitive to HbR, consequently measuring oxygenation and blood flow changes in
vessels with this technique is challenging.
3. Electron Paramagnetic Resonance Imaging (EPRI)36: EPRI requires the injection of
exogenous free-radical contrast agents.
4. Positron Emission Tomography (PET) and Single Photon Emission Tomography
(SPET)37,38: Both techniques require the injection of radioactive isotopes and suffer
from poor spatial resolution.
PA measurements of SO2 use the same principle as NIRS, where hemoglobin is considered
the dominant optical absorption chromophore at each wavelength (λi). The two forms of
hemoglobin, HbR and HbO2, have different molar extinction spectra (Figure 14), where the
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molar extinction coefficient is defined as the extinction coefficient of a substance at a specific
unit of concentration.
Thus, as a first order approximation, the blood absorption coefficient µa(λi) can be calculated
as follows:
(4)
(5)
where µa (cm−1) is the absorption coefficient; λ1 and λ2 are the two PA imaging wavelengths;
εox and εde are the known molar extinction coefficients (cm−1 mM−1) of the HbO2 and HbR,
respectively; Cox and Cde are the concentrations (mM) of the HbO2 and HbR. The SO2 and
HbT are defined as follows:
(6)
(7)
Since the localized PA amplitudes are proportional to the local optical energy deposition, one
can replace µa with the measured PA amplitudes. In addition, to minimize wavelength-
dependant fluence fluctuation, close wavelengths (i.e., 566 and 570 nm) are usually selected.
Many groups work on the correction of wavelength-dependant fluence fluctuation as well. It
is shown that even a simple difference between two images acquired using two appropriately
different wavelengths is correlated with the oxygenation of hemoglobin. More than two optical
wavelengths; however, are often used to improve accuracy.
3.2. Static and dynamic SO2 imaging in rats’ skin 9,16
The 50-MHz dark-field confocal PAM (see section 2.2.1) was employed for both static and
dynamic SO2 imaging in Sprague-Dawley rats (~200 g) in vivo. Four optical wavelengths (578,
584, 590, and 596 nm) were applied sequentially to get multicolored PA images. Figure 15A
shows morphological MAP image of blood vessels taken at 584 nm (isosbestic wavelength),
which reflects the total hemoglobin concentration. Vessel-by-vessel mapping of SO2 using Eq.
6 is shown in Figure 15B, estimated from the four images. Red color represents arterial blood
(SO2 = 0.97 ± 0.02) and blue color does venous blood (SO2 = 0.77 ± 0.04), and these values
agree well with values previously reported in the literature.39 With high-resolution PAM
system vessel-by-vessel SO2 mapping is possible, while the other techniques show only the
volume-averaged SO2.
For dynamic SO2 mapping, three physiological conditions (hyperoxia, normoxia, and hypoxia)
were induced in a rat by changing the oxygen concentration of the inhaled gases (pure oxygen,
normal air, and carbogen compromising 5% O2, 5% CO2, and 90% N2). The other imaging
protocols remained the same as in the static imaging experiment. Figure 15C shows the
morphological MAP image of blood vessels taken at 584 nm under hyperoxia. Figure 15D
shows the SO2 imaging under normoxia. Figure 15E shows the differential SO2 image between
normoxia and hypoxia (hypoxia – normoxia). In addition, the SO2 changes between normoxia
and hyperoxia (hyperoxia – normoxia) are shown in Figure 15F. The SO2 values in the arteries
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and veins under three physiological conditions are quantified in Figure 15G. The changes in
SO2 between the three conditions agreed well with the pulse oximeter readings and previously
reported results.40
3.3. Imaging brain hemodynamic changes in small animals6,15,41
First, a single-element unfocused ultrasound transducer based PACT (see section 2.1.1) was
employed to assess the cerebral blood volume and SO2 in brains of Sprague Dawley rats (~80
g) in vivo. Three physiological states (hyperoxia, normoxia, and hypoxia) were induced in a
rat by changing oxygen concentration in the inhaled gases as explained in section 3.2. Two PA
images were acquired at two optical wavelengths (584 and 600 nm) for each physiological
state. Figure 16A and B show the morphological images of the brain cortex under normoxia
taken at 584 and 600 nm, respectively, which match well with the photograph (Figure 16I)
taken after the imaging experiments. PA signals in Figure 16A are stronger than those in Figure
16B because the optical absorption coefficients of both types of hemoglobin are higher at 584
nm than at 600 nm (Figure 14). For the HbT and SO2 mapping using Eqs. 6 and 7, the cortical
venous regions were segmented from the background. Figure 16C and D show the mapping of
SO2 and HbT under normoxia, respectively. The SO2 image indicates the absolute value,
whereas the HbT image has an arbitrary unit. Figure 16E shows the differential <SO2>(the
averaged SO2 level) image between normoxia and hyperoxia (hyperoxia – normoxia).
Additionally, the <SO2>changes between normoxia and hypoxia (hypoxia – normoxia) are
shown in Figure 16F. Under hyperoxia, <SO2>in the cortical venous vessels was higher than
that under normoxia and as expected <SO2>under normoxia was higher than that under
hypoxia. The quantified <SO2>were ~ 80%, ~ 70%, and ~ 57% under hyperoxia, normoxia,
and hypoxia, respectively. Simultaneously, changes in the averaged HbT value, <HbT>, were
estimated during the changes of physiological states. Changes in <HbT>, denoted by <ΔHbT>/
<HbT>, from normoxia to hyperoxia was ~ 4% decrease (Figure 16G), whereas from normoxia
to hyperoxia was ~12% increase (Figure 16H). All segmented functional images in Figure 16E
to H were overlaid on the structural image in Figure 16B. These results agree well with the
previously reported results.40
Using the PACT system, functional brain activation in rats’ brain cortexes were studied in
response to left and right whisker stimulations in Sprague Dawley rats (~ 350 g). PA images
acquired without whisker stimulation were subtracted from images acquired with whisker
stimulation to map the brain activation. Figure 17A and B show functional cerebral
hemodynamic changes in response to left and right whisker stimulation, respectively. The
activated regions in PA images were marked on the open-skull photograph with two boxes
taken after the PA imaging experiments (Figure 17C). This region was histologically analyzed.
The vibrotome sections of cortical layer IV —whisker-barrel cortex in Figure 17D—
colocalized well with the activated regions in PA images. Increases in PA signals in those areas
could be explained as increase in blood volume and/or flow due to the whisker stimulation.
The 20-MHz dark-field confocal PAM (see section 2.2.1) was also employed to image brain
activity via the hemodynamic response in Swiss Webster mice (~ 25 g) in vivo. The real-time
oxygenation dynamics of the selected individual cortical vessels were measured
simultaneously in response to controlled perturbations of inhaled oxygen levels. Figure 18B
shows the morphological PA image of the brain cortex in the marked region in Figure 18A at
570 nm (isosbestic wavelengtht). After identifying several major somatoseonsory cortex (SC)
vessels in Figure 18B, a B-scan (Figure 18C) was obtained by raster scanning along the dashed
line in Figure 18B. The temporal resolution of one B-scan (Figure 18C) is less than one second.
Two optical wavelengths (561 nm: deoxyhemoglobin dominant wavelength, 570 nm: an
oxygen-insensitive absorption wavelength) were applied sequentially to get multicolored PA
images. The acquisition time for a pair of dual wavelength scans (10 s) was limited by the
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wavelength tuning time of the dye laser. Throughout image acquisition, hyperoxic (pure
oxygen: 100% O2) and hypoxic (carbogen: 5% O2, 5% CO2, and 90% N2) states were induced
by alternating the inhaled oxygen levels every 6 minutes, and a pulse oximeter was used to
verify each change. To estimate dynamic oxygenation changes, the integration of the full width
at half-maximum (FWHM) of the image of each vessel over the time period was calculated to
minimize the laser fluctuation effects. A hyperoxic state (100% O2) was used as a baseline,
and the animal was exposed to three 5% O2 steps with a return to baseline between successive
hypoxic states. Figure 19A shows the dynamic oxygenation profile for each of the five vessels,
and a close-up of the profile is shown in Figure 19C to emphasize the transition phases between
two physiological states. The baseline (isosbestic) measurement is shown in Figure 19B. The
initial step from hyperoxia to hypoxia occurred at time t = 6.1 min. The forward response time,
characterized by the rising time from 10 to 90% of maximum, was 63 ± 6 s. The forward
response time among the five vessels did not vary significantly (α = 0.1). Although the
maximum values under hypoxia significantly fluctuated among the vessels, no significant
correlation between maximum response and vessel diameter was observed. At t =12.2 min, the
hypoxic challenge ended via a step exposure to 100% O2. The reverse response time, defined
as the falling time from 90 to 10% of the maximum, was 16 ± 2 s.
3.4. Imaging tumor angiogenesis and tumor hypoxia in small animals13,42
Tumor angiogenesis43,44 describes the formation of new blood vessels around and within the
tumor and is a critical step in tumor growth. Angiogenesis increases the blood and nutrient
supply to the tumor, and consequently expedites tumor growth. During the normal angiogenesis
process, the balance of pro-and anti-angiogenic signals is tightly regulated, so new blood
vessels become quickly mature and stable. However, during the tumor angiogenesis, this
balance is not maintained and new vessels are constantly formed. The structures of these blood
vessels are different from normal vessels. They are typically abnormally shaped, dilated,
tortuous, and can have blind ends. In addition, these vessels are leaky and hemorrhagic from
overproduction of vascular endothelial growth factor (VEGF). Due to these differences, tumor
angiogenesis is an important parameter for tumor diagnosis and can be detected with PAT. A
single-element unfocused ultrasound transducer (3.5 or 20 MHz) based PACT (see section
2.1.1) was employed to image tumor angiogenesis in tumor-bearing brains of Sprague Dawley
rats (~100 – 200 g) in vivo. The mammary adenocarcinoma cell line (Br7-C5)45 was
transcranially injected (orthotopic inoculation, 105 monodispersed cells) into the brain cortex.
One month after the intracerebral inoculation, a tumor nodule (0.5 cm in diameter) developed
on the brain cortex. Figure 20A and B show two in vivo PA images of brain tumors, acquired
noninvasively with 3.5- and 20-MHz ultrasonic transducers, respectively. Two corresponding
close-up images of the tumors are shown in Figure 20 as well. The images were compared with
the open-skull photograph of the rat brain taken after the PA imaging in Figure 20C. Irregular
blood vessels with distorted shapes are easily recognized within the tumor shown in the two
images. Furthermore, hemorrhagic infiltration of the parenchyma due to leaky blood vessels
containing interendothelial junctions, an incomplete or absent basement membrane, and large
numbers of transendothelial channels can clearly be observed in the region of the tumor.46 In
the close-up image acquired with the 20-MHz transducer, the vessels show better delineated
boundaries, as expected.
Tumor hypoxia47,48 is a situation in which tumor cells lack oxygen. Some regions of the tumor
have lower oxygen concentration than healthy tissue. Tumor hypoxia is primarily caused by
unbalanced oxygen consumption compared with oxygen supply due to the abnormal tumor
vasculature. As described above, tumor vasculature is extremely abnormal and is marked by
random vascular dilations and networks, elongated and tortuous structures, and lack of flow
regulation. These effects cause severe deficiencies in the perfusion of oxygen and nutrients,
leading to ischemic hypoxia. In addition, those cells in the hypoxic zone are quiescent and
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prevent not only oxygen but also anti-cancer agents from penetrating. Tumor hypoxia is a
distinctive feature, important for tumor diagnosis, and can be imaged with PAT. A single-
element unfocused ultrasound transducer (10 MHz) based PACT (see section 2.1.1) was used
to image tumor hypoxia in tumor-bearing brains of nude mice (~ 20 g) in vivo. Human U87
glioblastoma tumor cells were inoculated stereotactically into mice. 1 × 106 cells of 7 µl were
inoculated intracranially into the caudate nucleus at a 3 mm depth from the skin surface.49 Four
optical wavelengths (764, 784, 804, and 824 nm) were applied sequentially to obtain spectrally
different PA images. Figure 21A and B show the SO2 (estimated with Eq. 6) and HbT
(estimated with Eq. 7) mapping on the tumor-bearing brain in a nude mouse, respectively. The
SO2 in the tumor region is lower than the surrounding blood vessels indicating tumor hypoxia;
the HbT is higher indicating probable angiogenesis. SO2 and HbT values from normal and
tumor vasculatures were quantified in Figure 21C. The averaged SO2 within the tumor is at
least 13% lower than in the normal vasculature. In addition, the SO2 level in the tumor is more
heterogeneous as indicated by the error bars. Hence, a relative HbT (rHbT)—defined as the
ratio of the local HbT to the mean HbT in the medium fissure of each mouse—is adopted.
Figure 21D show the plot of SO2 versus relative HbT (rHbT) between the normal and tumor
vasculatures. The normal vessels tend to have a lower rHbT, a higher SO2, and a lower SO2
fluctuation as compared to the tumor vessels.
3.5. Label-free functional chronic imaging of wound healing process using OR-PAM50
Chronic imaging of long-term microhemodynamics plays an important role in the studies of
disease progression,51,52 neural dynamics,53 and functional recovery from pathological
states.54 Since the current microvascular imaging techniques require invasive procedures and/
or fluorescence labeling, these effects disturb the normal physiology of the microcirculation,
discourage chronic studies, and impede clinical translations. By avoiding invasiveness and
photo-toxicity, label-free OR-PAM (see section 2.2.3) is an ideal imaging technique for chronic
microcirculation studies. The healing process of a laser-induced microvascular lesion in a nude
mouse ear was monitored over a period of 12 days. At each stage of the chronic imaging, the
corresponding transmission-mode optical microscopic photograph (left column in Figure 22)
was acquired along with an OR-PAM image (middle column in Figure 22) at 570 nm. The
SO2 values (right column in Figure 22) within the microvascular lesion were estimated using
two optical wavelengths, 570 nm (isosbestic point) and 578 nm (oxyhemoglobin dominant).
Directly after acquiring the images in Figure 22A, a microvascular lesion in the nude mouse
ear was created by 150-mW continuous wave (cw) laser illumination in the middle of the region
of interest (ROI). This ROI was imaged immediately after the cw laser treatment (Figure 22B),
and in the subsequent 12 days (Figure 22C, (C-1)–(C-12) using both the OR-PAM and a
conventional optical microscope. Four steps of the wound healing process were observed:55
(1) Vessel regression and hemostasis immediately following the laser treatment (Figure 22B);
(2) inflammation (in the forms of vasodilation), which began 24 hours after the injury and
lasted for about 5 days (Figure 22C, (C-1)–(C-5)). Hypoxia facilitated the synthesis of the
VEGF to trigger angiogenesis (Figure 22B and 22C, (C-1)–(C-5)); (3) the growth of new
capillaries, previously supplied by the damaged arteriole and observable after 3 days of the
treatment (Figure 22C, (C-3)); (4) after 12 days, the damaged arteriole-venule pair was almost
completely recovered (Figure 22C, (C-12)). The wound healing process could only partially
be monitored by the commercial transmission-mode optical microscope.
4. Functional and molecular PAT using exogenous contrasts
Intrinsic optical contrasts, such as hemoglobin and melanin, are highly promising for PAT, but
these contrasts significantly absorb light and generate strong PA signals in the visible spectral
region. Due to both strong optical absorption and scattering, the light penetration depth is quite
limited in this spectral region and the maximum imaging depth is shallow. To image in deep
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tissues, the use of near-infrared (NIR) light is highly desirable for optical imaging. Exogenous
contrast agents greatly enhance the sensitivity of PAT in the NIR spectral region. Additionally,
some biological targets do not have intrinsic optical absorption contrast for PAT in the visible
and near-infrared (NIR) regimes. One such important example is the lymphatic system.
Through the use of contrast agents in PAT, imaging sensitivity and specificity are significantly
improved just as in CT, PET, and MRI. Optically absorptive organic dyes, nanoparticles,
reporter genes and fluorescence proteins have been successfully applied as PA contrast agents.
4.1. Organic dyes
4.1.1. Indocyanine green (ICG)56,57—Indocyanine green (ICG) is a nontoxic, water-
soluble tricarbocyanine dye with a peak optical absorption at 790 nm.58 The penetration depth
of PA imaging using ICG can be increased using NIR light. The chemical structure of ICG is
shown in Figure 23. ICG is FDA-approved for determining human cardiac output, hepatic
function and blood flow, and ophthalmic angiography. Because ICG has a moderate
fluorescence quantum yield (~10% in DMSO and less than 1% in water)59, it emits a sufficient
amount of fluorescence and generates strong PA signals and as such can be used as a contrast
agent for both fluorescence and PA imaging. Typical optical, chemical, and physical
parameters of ICG are summarized in Table 1. The product of the molar extinction coefficient
profile and the nonradiative quantum yield (1 – fluorescence quantum yield) of ICG is shown
in Figure 31, where the effect of the internal conversion on the energy conversion is neglected.
Due to aggregation of ICG molecules, the spectrum of ICG in water is highly unstable as the
concentration is increased.60 The spectrum changes are also caused by protein binding.
A single-element unfocused ultrasound transducer (10 MHz) based PACT (see section 2.1.1)
was employed to assess the contrast enhancement in brain cortical structures in Sprague
Dawley rats (~150 g) in vivo. Polyethylene glycol (PEG) was used to stabilize the ICG, thereby
prolonging its circulation time in blood.61 This PEG conjugated ICG (ICG-PEG) highly
absorbs light around an optical wavelength of 805 nm. The ICG-PEG (the concentration = 320
µM) in phosphate buffered saline was injected intravenously through the tail vein. A dosage
of 0.25 ml/100 g body weight was administered and the estimated ICG concentration in blood
was ~ 10 µM. Based on the injection dose, the number of detectable molecules in one resolved
volume (60 µm × 60 µm × 60 µm with the z dimension limited by the blood vessel diameter)
is ~ 2 fmol per imaging voxel. Figure 24A and B show the noninvasive PA images of a rat
brain cortex before and after the ICG-PEG injection, respectively. The brain cortical structures
of two PA images match well with the photograph (Figure 24D) taken after the PA imaging.
The subtracted image (Figure 24C) between pre- and post-injection images shows increased
PA signals due to the ICG injection. Moreover, this subtracted image shows a more detailed
vasculature (indicated as black arrows in Figure 24C) than the images in Figure 24A and B.
To demonstrate the benefits of using contrast agents for deep PA imaging, the maximum
imaging depth was increased to 5.2 cm in biological tissues, imaged ex vivo. Three pairs of
transparent plastic tubes containing anticoagulation-treated whole rat blood, ICG solution in
water (323 mM), and ICG solution in blood (129 mM), were embedded in chicken breast tissues
of ~7.5-cm diameter in their transverse cross sections (Figure 25A). The optical coefficients
of blood, ICG in water, and ICG in blood are ~ 4–5 cm−1, 16 cm−1, and 43 cm−1 at 800 nm,
respectively.60 A single-element unfocused ultrasound transducer (2.25, 3.5, or 5 MHz) based
PACT (see section 2.1.1) was employed. Cross-sectional PA images were acquired by layering
chicken breast tissues, so the imaging depth from the laser illumination surface was increased
from 1.3 to 5.2 cm (Figure 25B). Figure 25C – F show the PA images obtained at various
depths (1.3, 2.6, 4.2, and 5.2 cm) using a 2.25-MHz transducer. The PA signals from the whole
blood are not visible below 2.6 cm deep. However, the PA signals from ICG in water and ICG
in blood are clearly discernible at depths reaching 5.2 cm. The PA signals from ICG in blood
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are stronger than those from ICG in water which agree well with the above mentioned optical
absorption coefficients of two solutions. Figure 25G and F show the cross-sectional PA images
at the depth of 5.2 cm using 3.5 and 5 MHz ultrasonic transducers, respectively. Despite lower
SNR’s at higher ultrasonic frequencies, the spatial resolution is better with the 5-MHz
transducer.
4.1.2. IRDye-800 as molecular imaging contrast agents42—ICG is hard to be
functionalized for labeling. IRDye 80062 is a water-soluble ICG derivative dye for protein/
antibody labeling applications. By adding the NHS ester reactive group, IRDye800-NHS is
able to be functionalized for labeling primary and secondary amino groups. The chemical
structure of IRDye800-NHS is shown in Figure 26. Typical optical, chemical, and physical
parameters of IRDye800-NHS are summarized in Table 1. The product of the molar extinction
coefficient profile and the nonradiative quantum yield of IRDye-NHS is shown in Figure 31.
A single-element unfocused ultrasound transducer (10 MHz) based PACT (see section 2.1.1)
was employed to image molecular contrast enhancement in nude mice (~ 20 g) in vivo using
IRDye800-NHS as a contrast agent. Human U87 glioblastoma tumor cells (1 × 106 cells of 7
µl) were inoculated intracranially into the caudate nucleus at a 3 mm depth from the skin
surface.49 IRDye800-NHS was conjugated with cyclic peptide cyclo(Lys-Arg-Gly-Asp-Phe),
which targets integrin αvβ3 (referred to as IRDye800-c(KRGDf)63). Since IRDye800 absorbs
light and emits fluorescence in the NIR regime; the former affects contrast in PACT and the
latter affects contrast in fluorescence imaging, it can be used as a contrast agent for both imaging
techniques. PAT was used to image the level of IRDye800-c(KRGDf) uptake in the brain tumor
xenograft. First, before the injection, simultaneous SO2 and HbT maps in the brain were
acquired (see section 3.4). Conventional planar fluorescence imaging was employed to confirm
the contrast-agent uptake. Integrin αvβ3 is overexpressed in newly formed tumor
microvasculatures and important in progression, angiogenesis, and metastasis of melanoma
and glioblastoma.64 Figure 27 shows the binding capability of IRDye800-c(KRGDf) to U87
tumor cells in vitro.
Twenty hours after the intravenous injection of IRDye800-c(KRGDf), the mice were imaged
first by a planar fluorescence imaging system and then by the PACT system. After the dual-
modality imaging experiments, the brain was histologically analyzed to validate the results.
The uptake of the IRDye800-c(KRGDf) in the tumor was first proven by the fluorescence
imaging in Figure 28A. Figure 28B and C show in vivo molecular PACT image of IRDye800-
c(KRGDf) and a composite image superimposing the segmented molecular PACT image
(ultrasonic frequency, 2.25 MHz; in-plane spatial resolution, 312 µm) onto the structural image
(ultrasonic frequency, 10 MHz; in-plane spatial resolution, 60 µm; optical wavelength, 804
nm) of the brain cortex, respectively. The uptake of the contrast agents is clearly seen in these
PA images.
4.1.3. Methylene blue (MB) as a contrast agent on sentinel lymph node (SLN)
mapping65—Methylene blue (MB)66,67 is a heterocyclic aromatic chemical compound
widely used in biology and chemistry. In biology, MB is used as a stain in bacteriology and as
an oxidation-reduction indicator.68,69 The chemical structure of MB is shown in Figure 29.
Typical optical, chemical, and physical parameters of MB are summarized in Table 1. The
product of the molar extinction coefficient profile and the nonradiative quantum yield of MB
is shown in Figure 31.
Sentinel lymph node biopsy (SLNB), i.e., the biopsy of the first lymph node receiving drainage
from a cancer-containing area, has become the standard procedure for staging breast cancer
patients to reduce the postoperative complications of axillary lymph node dissection (ALND).
70 Although SLNB with blue dye (lymphazurin blue or methylene blue) and radioactive tracers
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has an identification rate of 90–95% and a sensitivity of 88–95%, these methods still require
ionizing imaging tools and intraoperative procedures. Moreover, they can fail to identify
axillary disease owing to a false negative rate of 5–10%.71 SLNB, despite being less invasive
than ALND, still poses significant side effects.72 Recently, ultrasound-guided fine needle
aspiration biopsy (FNAB) has been tested and clinically evaluated as a minimally invasive
biopsy procedure.73 However, this technique requires accurate identification of the SLN.
Therefore, there is still a pressing need to develop an accurate, non-ionizing, and noninvasive
detection method for lymph node assessment. Thanks to the strong optical absorption
coefficient of MB, PA imaging can be an alternative method to localize a SLN both accurately
without the use of any ionizing radiation. In the United States, lymphazurin blue (LB)74 is the
only dye approved by FDA for SLN identification in breast surgery. However, LB causes
following the complications: allergic and anaphylactic type I hypersensitivity reactions, skin
pigmentation, and discoloration of body fluids. In addition, the supply of LB is insufficient
and LB is more expensive than MB. MB is more widely used in SLNB because it is more
readily available and cost-effective. Furthermore, although MB causes more skin staining, no
anaphylaxis has been reported for SLNB.
A deep reflection-mode PAM system (see section 2.2.2) was employed to map SLNs
noninvasively in Sprague Dawley rats (~ 250 – 350 g) using MB. An ultrasonic frequency of
5 MHz and an optical wavelength of 635 nm were used in this system. The incident laser fluence
on the rat skin was 3.4 mJ/cm2, within the ANSI safety limit (20 mJ/cm2).22 After removing
hairs on the rat skin, a control image was acquired. 0.07 ml of 1% MB (10 mg/mL) was
intradermally injected on a left forepaw pad. After the administration of MB, a series of PA
images were acquired. Figure 30A and B show photographs of a rat taken before and after
image acquisition, respectively. After PA imaging, the rat’s skin was removed to identify the
MB dyed lymph node (Figure 30B). The surrounding vasculature in the axillary area is clearly
seen with an image contrast of 7 ± 0.5 with respect to the background in the control image
(Figure 30C). The SLN appeared immediately after the injection of MB with an image contrast
of 12 ± 2, seen in Figure 30D. The SLN was still observed 50 min post-injection after the scan
head was repositioned (Figure 30E). The mean depth of top surface of human SLNs is 12 ± 5
mm in ultrasonography. To determine the feasibility of PAT in human SLN imaging, the
imaging depth was increased to 18 mm by adding chicken tissues on top of the rat. Although
the blood vessels faded away, the SLN is still clearly seen in Figure 30F.
Table 1 summarizes the optical, chemical, and physical parameters of organic dyes. The
product of the molar extinction coefficients and nonradiative quantum yield values, defined as
the difference of the fluorescence quantum yield from 1, of various organic dyes are shown in
Figure 31. The molar extinction coefficients of oxy (HbO2) and deoxyhemoglobin (Hb) are
also plotted in the same figure.
4.2. Nanoparticles
Nanoparticles have received considerable attention in biomedical applications, since it has been
proven that they can be utilized effectively for delivering75,76 and targeting77,78 therapeutic
agents to a specific site and as contrast agents for diagnostic purposes.78–80 Due to their tunable
properties such as sizes, shapes, and compositions, nanoparticles are widely used to enhance
image contrasts throughout biomedical imaging fields, including optical imaging,78,81,82
magnetic resonance imaging (MRI), 83–85 and x-ray computed tomography (CT).86,87 The
basic theories and fabrication processes of gold nanostructures (gold nanospheres, gold
nanoshells, gold nanorods, and gold nanocages) used in PAT were reviewed in ref 88. In this
article, the biomedical applications of gold nanostructures in conjunction with PAT will be
reviewed.
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4.2.1. Gold nanocages89,90—Gold nanocages are hollow porous nanoparticles with a
broad range of sizes (35–100 nm). Gold nanocages have been used as a contrast agent in PA
imaging because of biocompatibility, easily modifiable surfaces for targeting,91,92 a lack of
heavy metal toxicity,93 a tunable localized surface plasmon resonance (LSPR) peak,
encapsulated site-specific drug delivery,94 and strong optical absorption in the NIR spectral
region.38,91
Gold nanocages were prepared by titrating silver nanocubes with aqueous HAuCl4.94–100
Silver nanocubes with an edge length of ~30 nm (Figure 32A) were synthesized using a
polymer-mediated polyol method, which involves reduction of silver nitrate by ethylene glycol
at 160 °C.101–103 In general, the size of the nanocubes could be varied by controlling the
reaction time. The silver nanocubes can then serve as sacrificial templates and be converted
into gold nanocages via a galvanic replacement reaction,
, with HAuCl4 in water under refluxing (Figure
32B). The edge length of the subsequent gold nanostructure increased from 30 to 36 nm because
the gold was deposited around the outer surface of the silver template. The ensuing gold
nanocages have a strong absorption peak, determined by the ratio of the wall thickness to edge
length. Experimentally, we can easily and precisely control this parameter by varying the molar
ratio of Ag to HAuCl4 in a fashion similar to acid-base titration. Figure 32C shows the
extinction spectra measured for the 30-nm silver nanocubes and the resultant gold nanocages
with the extinction peak specifically tuned to 800 nm. Using the discrete dipole approximation
(DDA) method, we can predict the exact scattering and absorption components (Figure 32D)
for the gold nanocages. The calculated and measured spectra agree well in terms of peak
position. Calculations indicate that absorption is predominant for gold nanocages <50 nm in
size.104
Using established alkanethiol chemistry, the surface of the gold nanocages can be easily
functionalized with tumor-targeting moieties such as antibodies or polypeptides. 104 For
instance, the surface of gold nanocages can be derivative with thiol molecules containing the
poly-ethylene-glycol (PEG) segment and N-hydroxysulfosuccinimide (NHS) terminus, a facile
leaving group for amide bond formation. The NHS terminus can be coupled into the antibodies
(Figure 33A). To confirm the effectiveness of bioconjugation, the targeting specificity was
studied in vitro. As an example, a breast cancer cell line (SK-BR-3), which is known to
overexpress HER2 receptor on its surface, was chosen for demonstration. Monoclonal
antibodies (i.e. anti-HER2) were employed to target the receptors. Figure 33B shows a scanning
electron microscopy (SEM) image taken from a representative cancer cell whose surface was
directly targeted with anti-HER2-derivatized gold nanocages, revealing the molecular
specificity and high coverage of nanocages on the cell surface. As a control, the SK-BR-3 cells
were incubated with PEGylated gold nanocages that did not have anti-HER2 attached. The
SEM image (Figure 33C) shows essentially no gold nanocages on the cell surface. These results
demonstrate that the immuno gold nanocages can selectively target the specific receptor
expressed on cancer cell surface.
A single-element unfocused ultrasound transducer (10 MHz) based PACT (see section 2.1.1)
was employed to confirm the contrast enhancement of gold nanocages for PA imaging in
vivo. PEGylated gold nanocages were injected into Sprague Dawley rats (100 – 150g) via the
tail vein and PA images of its cerebral cortex were recorded. Three successive injections of
nanocages were administrated, each with a dose of ~0.8 × 109 nanocages/g body weight. The
data were acquired before and after injection up to 3 hours with a optical wavelength of 804
nm. Figure 34A shows the structural image of the rat brain, measured from intrinsic optical
contrast, before injection of PEGlyated nanocages, while Figure 34B shows a better resolved
image of the same rat brain after the injection. Figure 34C shows the subtracted image between
the pre-injection image (Figure 34A) and the post-injection image (Figure 34B). All PA images
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of the rat brain cortex (Figure 34A–C) match well with the open-skull anatomical photograph
in Figure 34D. The enhancement of PA signals due to gold nanocages was quantified as a
function of time in Figure 34E. At 2 hours after the final injection, the PA signal was increased
maximally by ~ 81%, after which the signal gradually cleared out from the blood.
In another demonstration, 100 µL of 2 nM gold nanocage solutions were intradermally injected
on the left forepaw pads of Sprague Dawley rats (250 – 350 g) to image sentinel lymph nodes
noninvasively. The deep reflection-mode PAM system (see section 2.2.2) was employed.
Figure 35A shows a photograph of the axilla of a rat after the hair was removed and before PA
imaging. The photograph in Figure 35B shows the same region of the rat with the skin removed
and the SLN containing gold nanocages after the PA imaging. The control image is shown in
Figure 35C, captured prior to the injection of gold nanocages. The surrounding vasculature is
clearly seen in the control image. The SLN was detectable about 5 min after the injection
(Figure 35D). Figure 35E–G show the time-course of PA images acquired at 54 min, 135 min,
and 189 min after the injection, respectively. Figure 35H shows the increase of PA signal in
the SLN as a function of time. As time elapsed, the gold nanocages gradually accumulated and
the PA signal within the SLN was increased. The peak accumulation time of gold nanocages
in the SLN was observed to be about 140 min after the injection.
4.2.2. Gold nanoshells82,105,106—Gold nanoshells comprised of silica cores (~116 nm in
diameter) coated with an thin gold shell (~14 nm) have widely tunable plasmon resonances in
the visible and near-infrared regimes.107 The absorption peaks of these nanoshells are tunable
by varying the core size relative to the thickness of the gold shell. In addition, the optical
absorption properties of the gold nanoshells also depend on rigid metallic structures, unlike
organic dyes, whose optical properties are determined by molecular orbital electronic
transitions. Due to their excellent biocompatibility, gold nanoshells have been widely used in
photothermal therapy108 and as diagnostic contrast agents.82,105 PEGylated gold nanoshells
has longer blood circulation time.
A single-element unfocused ultrasound transducer (10 MHz) based PACT (see section 2.1.1)
was employed to confirm the contrast enhancement of gold nanoshells for PA imaging in
vivo. The extinction spectrum of the gold nanoshells peaked at 800 nm, accordingly an 800 nm
laser excitation wavelength was used in PA imaging. PEGylated gold nanoshells were injected
into Sprague Dawley rats (130 – 160g) via the tail vein and then a series of PA images were
acquired of their cerebral cortexes. The nanoshells were administrated three times successively.
Each dose was ~0.8 × 109 nanoshells/g body weight. After the final injection, the rat brain was
imaged sequentially 10 times for more than ~6 h. Figure 36A shows the brain cortical
vasculature before injection of PEGlyated nanoshells. A PA image of rat brain cortex is shown
in Figure 36B, acquired ~20 min after the injection. Figure 36C shows the subtracted image
between the pre-injection image (Figure 36A) and the post-injection image (Figure 36B). This
image shows the distribution of increased optical absorption in the rat brain due to the injection
of PEGlyated nanoshells. All PA images of the rat cerebral cortex (Figure 36A–C) match well
with the open-skull anatomical photograph in Figure 36D taken after the PA imaging. The
time-course PA signal increase was quantified in Figure 36E. The maximal increase of PA
signal was ~ 63%. After that, the signal gradually decreased.
In another demonstration, the 50-MHz dark-field confocal PAM (see section 2.2.1) was
employed to image progressive extravasation and accumulation of nanoshells within a solid
tumor in vivo. Immunocompetent BALB/c mice (~ 20g) were inoculated with CT26.wt murine
colon carcinoma cells subcutaneously on the mice brains. Imaging was performed 7 days after
tumor inoculation. PEGylated nanoshells with a peak optical absorption at 800 nm were then
intravenously administered at a dose of 1.4 × 109 nanoshells /g body weight. A control imaged
prior to the nanoshell injection was acquired in Figure 37A. After the injection, the
Kim et al. Page 15
Chem Rev. Author manuscript; available in PMC 2010 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
extravasation and accumulation of nanoshells in and around the tumor was monitored for 6 h.
Figure 37B – D shows the passive uptake of nanoshells at the tumor at 1.4, 3, and 5.8 h post-
injection, respectively. As time elapsed, the accumulation of nanoshells at the tumor is clearly
evident. Time-dependent PA signal enhancement in the vessels and tumor from the injection
is shown in Figure 37E. At 5.8 h post-injection, the image contrast ratio of tumor to vessels is
~6.5.
A single-element focused ultrasound based PAM (48 MHz)106 was employed to investigate
the feasibility of molecular PA imaging of specific tumors using targeted spherical gold
nanoparticles. Three tissue phantoms with human epithelial carcinoma cells (A431
keratinocyte) were tested: (1) a control phantom without any nanoparticles; (2) a targeted
phantom with EGFR (epithelial growth factor receptor) targeted gold nanoparticles; and (3) a
non-targeted phantom with PEGylated gold nanoparticles. The absorbance spectra of the
control, targeted, and non-targeted phantoms are shown in Figure 38A. The non-targeted
phantom has a peak absorbance at 520 nm, while the peak absorbance of the targeted phantom
has red-shifted and broadened due to EGFR-mediated aggregation of gold nanoparticles.109
In the control phantom, the absorbance is significantly lower throughout a wide spectral range.
Based on the Figure 38A, the PA images of three phantoms shown in Figure 38B, D and F
were acquired at the optical wavelength of 532 nm. The other three images, Figure 38C, E and
G were obtained at 680 nm. Nothing is shown in the control images at both wavelengths in
Figure 38B and C, which agrees well with the absorbance spectrum of the control phantom.
Stronger PA signals are observable from the non-targeted phantom (Figure 38F) than from the
targeted phantom (Figure 38D) at 532 nm; whereas opposite results were recovered when
illuminated with an optical wavelength of 680 nm. These results agree well with the absorbance
spectra in Figure 38A.
4.2.3. Gold nanorods18,110–113—Since gold nanorods possess dielectric properties in the
NIR, they have strong and narrow optical absorption band in this regime. Additionally, gold
nanorods have biocompatibility, surfaces that are easily modifiable and amenable for targeting,
a lack of heavy metal toxicity, and a readily tunable LSPR peak. Due to these properties, gold
nanords have been widely used in photothermal therapy114 and as diagnostic contrast agents
in PAT.18,110–113
A single-element focused ultrasound based PAM (50 MHz)112 was employed to demonstrate
the feasibility of PA imaging of inflammatory responses using bioconjugated gold nanorods
in vitro. The aspect ratio of gold nanorods was 3:1 and the peak wavelength of optical
absorption was at 700 nm. Intercellular adhesion molecule-1 (ICAM-1) is a strong
inflammatory mediator in systemic inflammatory diseases such as rheumatoid arthritis (RA).
115 Anti-intercellular adhesion molecule-1 (anti-ICAM-1) was selected as a biomarker of
inflammation and activation of endothelial cells (ECs), which binds to cell surfaces over
expressing ICAM-1. Unstimulated and stimulated ECs were incubated with gold nanorods
bioconjugated with anti-ICAM-1, photoacoustically imaged, and compared. Non-
bioconjugated gold nanorods (blank gold nanorods) incubated in both unstimulated and
stimulated ECs. 1012 nanorods/ml were used as a control for all experiments. PA signals from
stimulated ECs with bioconjugated nanorods (Figure 39A) were 10 dB stronger than those
from unstimulated ECs with bioconjugated nanorods (Figure 39B). This result implies ICAM-1
was over expressed on the surfaces of stimulated ECs and anti-ICAM-1 conjugated nanorods
were highly bound to the cell surfaces. When blank nanorods were used, PA signals from both
stimulated and unstimulated ECs did not increase significantly, as seen in Figure 39C and D,
respectively. This reflects very low nonspecific binding efficiency of blank nanorods to ECs.
The custom-made ultrasonic array based PA imaging system111 was employed to investigate
the feasibility of preclinical and clinical applications of PA imaging using gold nanorods as a
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contrast agent. A nude mouse was positioned on top of the ultrasonic array system, and light
illuminated from the top. The PA imaging system consists of two parallel linear arrays of 32
acoustic transducers equipped with a real-time multichannel signal processor. The excitation
laser wavelength of 757 nm was close to the peak wavelength of optical absorption of the
nanorods. Using a single channel acoustic transducer, the minimum sensitivity was measured
in nude mice. First, PBS (25 µL) was injected subcutaneously into the abdominal area of the
mouse and a control PA image was acquired. Then, PEGylated gold nanorods with a
concentration of 1.25 pM (7.5 × 108 nanorods/ml) were injected subcutaneously. The localized
PEGylated gold nanorods are clearly seen in the subcutaneous (SQ) tissue, where the gold
nanorods were injected, in Figure 40A. Using the ultrasonic array based PA imaging system,
the PA signal enhancement due to gold nanorods was observed in a nude mouse in vivo.
PEGylated gold nanorods of 100 µL with a concentration of 7.5 × 1010 nanorods/ml were
subcutaneously injected into the abdominal area of the mouse. Figure 40B and C show two PA
images before and after the nanarod injection, respectively. The injected gold nanorods are
clearly seen in Figure 40C with an image contrast of 9:1 compared to the background.
A custom-made single-element ultrasound transducer based PAM (20 MHz)18 was employed
to demonstrate the feasibility of molecular PA imaging of malignant tumors using
bioconjugated gold nanorods (AuNRs) in vivo. Two types of tumor cell lines were used in this
study: 1) oral cancer OECM1 (oral squamous cell carcinoma) cells overexpressed with HER2
(human epidermal growth factor receptor 2) on the cell surface, and 2) Cal27 (squamous cell
carcinoma) cells overexpressed with EGFR (epidermal growth factor receptor). For multiple
targeting, two types of gold nanorods were tested: 1) AuNR785-HER2 (peak absorption
wavelength, 785 nm; aspect ratio, 3.7; conjugated antibody, anti-HER2 for targeting OECM1
cells) and (2) AuNR1000-EGFR (peak absorption wavelength, 1000 nm; aspect ratio, 5.9;
conjugated antibody, anti-EFGR for targeting Cal27 cells). Two optical wavelengths, 800 and
1064 nm, were used for AuNR785-HER2 and AuNR1000-EGFR, respectively. The AuNRs were
coated with poly(ethylene glycol) (PEG). The PEG-AuNRs (referred to as AuNRs) without
any bioconjugation were used for control experiments. A 100 µL of AuNRs were injected to
mice in each study at concentration of 30 nM. Figure 41 shows time-course co-registered
ultrasonic (US, gray color scale) and PA (red color scale) images of Cal27 tumors before and
after the injections of AuNR1000 and AuNR1000-EGFR, independently. The contoured area
indicates the tumor region in Figure 41A and B. Within the tumor region, the PA image contrast
with the injection of AuNR1000-EGFR at 7hr post-injection is higher than the contrast prior to
the injection (Figure 41A). When AuNR1000 were injected, there is no apparent difference in
PA images between pre- and post-injections (Figure 41B). The time-dependant PA signal
enhancement within the tumor region was quantified in Figure 41C. The contrast using
AuNR1000-EGFR is maximally ~3.5 dB higher than that using AuNR1000 at 7h post-injection.
Figure 42 shows time-course co-registered ultrasonic (US, gray scale) and PA (red scale)
images of OECM1 tumors before and after the injections of AuNR785 and AuNR785-HER2,
independently. Within the tumor region, the PA image contrast obviously increased 1 hr to 17
hr post-injection of AuNR785-HER2 as compared to the contrast prior to the injection (Figure
42A). When AuNR785 was injected, there is no apparent difference in PA images between pre-
and post-injections (Figure 42B). The time-dependant PA signal enhancement within the tumor
region was quantified in Figure 42C. The contrast using AuNR785-HER2 is maximally ~2 dB
higher than that using AuNR785 at 14 hr post-injection.
In another demonstration, 100 µL of a 979-pM gold nanorods (AuNRs) solution was injected
intradermally in the left forepaw pads of Sprague Dawley rats (~ 400 g) to noninvasively image
sentinel lymph nodes in vivo. The deep reflection-mode PA imaging system (see section 2.2.2)
was employed. The AuNRs used for this study had a 10 nm diameter, a 41 nm length, and a
peak absorption wavelength of 807 nm. Figure 43A shows a photograph of the axilla of the rat
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after the hair was removed before PA imaging. Figure 43B shows a photograph of the same
region with skin removed and shows the SLN containing AuNRs after the PA imaging, and
the top and bottom views of the excised SLN. The control image is shown in Figure 43D
captured prior to the injection of AuNRs. The surrounding vasculature is clearly seen in the
control image. The SLN was not detectable until 19 hr post-injection (Figure 43E and F). At
46 hr post-injection, the SLN was clearly seen with good contrast in, shown Figure 43G. The
depth-resolved B-scan along the dotted line in Figure 43G shows the depth information of SLN
and blood vessels in Figure 43C.
4.2.4. Single-walled carbon nanotubes19,116–118—Although the toxicity of carbon
nantubes is still an ongoing debate in biomedical applications,119–121 single-walled carbon
nanotubes (SWNTs) were tested in PA imaging as a contrast agent for molecular specific tumor
targeting19,118 and sentinel lymph node mapping in vivo.116 SWNTs were also investigated
as agents for photothermal therapy.122 The synthesis of SWNTs used in PA imaging is
explained in detail in refs. 116,117.
A single-element focused ultrasound transducer based PAM system (5 MHz)19 was employed
to investigate the feasibility of molecular PA imaging of malignant tumors using bioconjugated
SWNTs in vivo. SWNTs (1–2 nm in diameter and 50–300 nm in length) were coupled to the
RGD peptides123 (SWNT–RGD) through polyethylene glycol-5000 grafted phospholipid (PL–
PEG5000) (Figure 44A). The SWNT–RGD targets to αvβ3 integrin overexpressed in tumor
neovasculature. For control experiments, only PEGylated SWNTs (Plain SWNT) were
synthesized without any biomarkers. Figure 44B shows the optical absorption profiles of oxy-
hemoglobin (HbO2), deoxy-hemoglobin (Hb), plain-SWNT, and SWNT-RGD. These profiles
suggest that 690 nm is preferable for PA imaging. The PA sensitivity measured using SWNTs
in biological tissues is 50 nM, that is, the PA signal from tissues (background) was equal to
the PA signal from 50 nM of SWNTs (SNR = 1).
200 µL of SWNT-RGD at a concentration of 1.2 mM was intravenously injected via the tail-
vein to U87MG tumor xenografts bearing mice (n = 4). The same amount and concentration
of plain-SWNT was intravenously injected as well (n = 4). A series of US and PA images
around the tumor bearing region were acquired before and up to 4 h after injection. Figure 45A
shows the time-dependant increase of PA signals in mice after the injection of SWNT–RGD
and plain-SWNT. The PA images of mice injected with SWNT-RGD shows significant signal
enhancement within the tumor region. A differential image between the PA images taken at 4
h post-injection and the image taken before injection clearly prove the accumulation of SWNT-
RGD within the tumor, compared to the differential image using plain-SWNT. The PA signal
increase was quantified as a function of time (Figure 45B). On average, the PA signals using
SWNT-RGD is ~ 8 times greater than using plain-SWNT at 4 h post-injection.
In another demonstration, 75 µL of a 500 nM SWNTs solution was intradermally injected in
the left forepaw pads of Sprague Dawley rats (~ 250 – 350 g) to image sentinel lymph nodes
in vivo noninvasively. The deep reflection-mode PA imaging system (see section 2.2.2) was
employed. The optical wavelength of 807 nm was utilized. The control image captured prior
to the injection of SWNTs is shown in Figure 46A. The surrounding vasculature is clearly seen
in the control image. The SLN appeared immediately after the injection (Figure 46B). Figure
46C – E show the PA images of the same area 30, 55, and 85 min post-injection of SWNTs.
The uptake kinetics of the SWNTs is shown in Figure 46F.
4.2.5. Colloidal gold nanobeacons124—Colloidal gold nanobeacons (GNBs) are soft,
hollow colloidal particles containing smaller gold nanoparticels (2–4 nm) inside. Based on the
high optical absorption in the visible and NIR regimes, GNBs can be used as molecular contrast
agents in PA imaging. The GNBs have a nominal hydrodynamic diameter of 154 ± 10 nm
Kim et al. Page 18
Chem Rev. Author manuscript; available in PMC 2010 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(Figure 47). The benefit of the bigger size of GNBs than other gold nanostructures (< 50 nm)
is that the GNBs have greater chance to stay in blood stream and lead to specific targeting.
Smaller particles can rapidly distribute beyond the vasculature and into tissues and bind to
nonspecific targets, consequently causing an unwanted signal increase in background. The
fabrication process of GNBs is described in detail in the ref 124.
A solution of GNBs (3 ml/kg) was intravenously injected to a Sprague Dawley rat to
preliminarily test noninvasive in vivo blood-vessel imaging of a femoral vein. The deep
reflection-mode PAM system (see section 2.2.2) was employed, using an optical wavelength
of 766 nm. The control image captured prior to the injection of GNBs is shown in Figure 48A.
The vasculature is clearly seen in the control image with a contrast-noise ratio (CNR) of 50.
Figure 48B shows the PA image (CNR = 68) of the same area 156 min after the injection. The
PA signal in blood vessels increased up to 60% after injection as compared to that in control
image. Figure 48C shows the time-course PA signal enhancement after the injection.
4.2.6. Nanowontons125—Composite-material nanoparticles, “nanowontons”, were
recently introduced at contrast agents for MRI and PAT. The nanowontons have a cobalt (Co)
core for MRI and gold (Au) thin film coating. The nanowontons exhibit both ferromagnetic
and optical responses, making them useful for dual-modality MRI and PAT studies. The shape
and thickness of the Au capping layer is designed to match the peak optical absorption
wavelength in the NIR (700 nm) regime. The fabrication process of nanowontons is explained
in detail in the ref.125. The optical absorbance of nanowontons is shown in Figure 49A. Figure
49B shows the PA images of a tissue phantom containing 4 optically absorptive targets at
various concentrations of nanowontons: 100, 50, 25, and 13 pM. The detection sensitivity of
this system is on the order of 25 pM.
4.2.7. Quantification of optical absorption cross-sections of gold
nanostructures using photoacoustic sensing126—Gold nanostructures can have a
strong extinction peak (localized surface plasmon resonance) in the visible and near-infrared
(NIR) regimes. This extinction peak is comprised of two components: scattering and
absorption. By changing the size, shape, and internal structure of the nanostructures, the relative
magnitude of light being absorbed and scattered can be tuned. In general, different applications
may require nanostructures to possess very specific optical properties. For example, optical
scattering dominant nanostructures can be used as a contrast agent in optical coherence
tomography, and optical absorbing dominant nanostructures are more valuable to PA imaging.
Therefore, it is essential to know both the absorption (σa) and scattering (σs) cross-sections of
a nanostructure for a specific biomedical application.
A conventional UV-vis-NIR spectrometer measures the extinction spectra of nanostructures,
which eventually provides the extinction cross-section (σe, with σe = σa + σs) of the
nanostructures. Currently, theoretical simulation is the dominant method to separate σe into
σa and σs. The Mie theory has been used for spherical particles, while the discrete-dipole
approximation (DDA) is for other shapes of nanostructures.
The σa of gold nanostructures can be experimentally measured using PA sensing. The PA signal
is primarily sensitive to optical absorption and the signal is directly proportional to the
absorption coefficient (µa) of the material. Therefore, PA signals from nanostructures at
various concentrations can be converted into the corresponding µa by comparing it against a
known linear calibration curve that (e.g., methylene blue or indocyanine green) describes the
relationship between the PA signal and the µa of an organic dye. Then σa can be obtained by
dividing µa by each corresponding concentration. When combined with the conventional UV-
vis-NIR spectroscopic measurement, the σe, σa, and σs of the nanostructure can be determined,
independently.
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Table 2 shows that the ratios of absorption to extinction cross-sections (σa/σe) obtained from
experimental results, which agree well with theoretical calculations. This agreement
demonstrates that the PA sensing based technique can be used to measure the absorption and
scattering cross-sections of gold nanostructures.
4.3. Reporter genes127,128
In gene expression imaging, an exogenous reporter gene can be incorporated into the genome
of a tumor cell line and its expression can be controlled by a promoter. Eventually, the
expression products of the reporter gene by the promoter can be used as contrast for imaging,
either directly or indirectly via some assay. Since many diseases like cancer are related to
genetic disorders, imaging of gene expression could potentially play an important role in
molecular imaging.
The dark-field confocal PAM (50 MHz, see section 2.2.1) was employed to image the
expression of lacZ reporter gene in a brain of a Sprague Dawley rat (80–100 g) in vivo. The
lacZ reporter gene encodes β-galactosidase, an E. coli enzyme for lactose metabolism. 5-
bromo-4-chloro-3-indolyl-β-d-galactoside (X-gal), a sensitive colorimetric assay, was used for
β-galactosidase staining. A blue product is created when β-galactosidase cleaves the X-gal’s
glycosidic linkage, and this blue product has strong optical absorption (Figure 50).
Consequently, this provides strong contrast for PA imaging.
9L/lacZ gliosarcoma tumor cells were inoculated to the scalp of a rat. When the tumor was
visible, 20 µL of an X-gal solution (20 mg/ml) was administrated near the tumor one day before
PA imaging. Figure 51A shows the PA imaging at an optical wavelength of 635 nm of the
lacZ-marked 9L gliosarcoma after X-gal staining. The tumor, enhanced by blue product, is
clearly seen. Without X-gal staining, the tumor was not observable in the PA image. The
surrounding microvasculature was imaged at the wavelength of 584 nm in Figure 51B. Figure
51C shows a composite image of both blood vessels (Figure 51B) and the tumor (Figure 51A)
with enhanced contrast by the blue product.
4.4. Fluorescence proteins129
Fluorescence protein imaging has become increasingly important in biological and medical
research.130 However, due to the shallow imaging depth (~1mm) of fluorescence microscopy,
the applicability of fluorescence proteins is quite limited. As mentioned in section 4.1, PA
signals are proportional to the product of the molar extinction coefficient and the nonradiative
quantum yield (1 – fluorescence quantum yield) of a contrast agent. Thus, fluorescence proteins
possessing less fluorescent quantum yields can be great candidates as contrast agents for PA
imaging. Furthermore, since a deeper imaging depth is possible with PA imaging, molecular
PA imaging with fluorescence proteins has great potential in biology and medicine. Table 3
summarizes the optical properties of several fluorescence proteins.
A single-element cylindrically focused ultrasound transducer based PACT system129 was
employed to image the expression of mCherry in the head of an adult transgenic zebrafish in
vivo. Figure 52A shows the morphological cross-sectional PA images of the head at various
depths. The structural PA image in Figure 52B matches well with the corresponding histology
in Figure 52C. The map of mCherry expression was overlaid on the structural PA image taken
at 585 nm in Figure 52D. The mCherry expression is clearly seen in the PA image, which well
correlates with the corresponding epifluorescence image of the dissected brain (Figure 52E).
5. Summary
In summary, two types of PAT modalities have been reviewed: 1) inverse-algorithm based
PACT and 2) direct-raster scanning based PAM. PAT has the following features. 1) PAT breaks
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through the fundamental imaging depth limit of high-resolution optical microscopy. Both the
imaging depth and the spatial resolution are scalable with ultrasonic frequency and can be tuned
for specific imaging requirements. 2) The image contrast of PAT is primarily derived from
optical absorption, unlike pure optical microscopy. 3) With ultrasonic arrays, PAT can acquire
images in real time. 4) PAT uses nonionizing radiation, is safe for humans, and is ready for
use in clinical applications. 5) PAT provides morphological and functional (oxygen saturation
of hemoglobin and total hemoglobin concentration) imaging using intrinsic contrast
(hemoglobin or melanin). 6) PAT provides functional (sentinel lymph node mapping) and
molecular (tumor specific) imaging using exogenous contrast agents (organic dyes,
nanoparticles, reporter genes, or fluorescent proteins).
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Figure 1.
Illustration of the PA mechanism. When a target absorbs light, PA waves are generated via
thermo-elastic expansion. The PA waves propagate and are detected by an ultrasonic
transducer.
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Figure 2.
Circular scanning geometry in PACT using an unfocused ultrasound transducer.
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Figure 3.
A schematic of a PACT system for small-animal brain imaging. (Reprinted with permission
from ref 82. Copyright 2006 American Chemical Society.)
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Figure 4.
Structural PACT image of a rat brain acquired in vivo. (A) Noninvasive PACT image of a rat
brain cortex acquired with the skin and skull intact. C, cerebellum; H, cerebral hemispheres;
O, olfactory bulbs; MCA, middle cerebral artery; CS, cruciate sulcus; FT, fissure transversa;
V, blood vessels. (B) Open-skull photograph taken after PACT experiment. (Reprinted with
permission from ref 6. Copyright 2003 Nature.)
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Figure 5.
A schematic of 512-element, 360-degree PACT system. (Reprinted with permission from ref
7. Copyright 2009 The Optical Society of America.)
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Figure 6.
Time-resolved PA images of mouse brain vasculature with fast wavelength scanning. The laser
wavelength was manually chirped from 710 nm to 900 nm over 30 seconds. (Reprinted with
permission from ref 7. Copyright 2009 The Optical Society of America.)
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Figure 7.
Schematic of a microscopic PACT imaging system using a linear ultrasound array. (Reprinted
with permission from ref 23. Copyright 2008 Society of Photo-Optical Instrumentation
Engineers.)
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Figure 8.
(A) In vivo noninvasive PA image of subcutaneous blood vessels in a rat using microscopic
PACT with a linear ultrasound array. The regions enclosed by major blood vessels are labeled
using A–E. (B) Photograph taken from the dermal side of the excised skin with transmission
illumination. (Reprinted with permission from ref 23. Copyright 2008 Society of Photo-Optical
Instrumentation Engineers.)
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Figure 9.
Experimental dark-field confocal PAM system. (Reprinted with permission from ref 9.
Copyright 2006 Nature.)
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Figure 10.
In vivo noninvasive PA images of subcutaneous microvasculature, melanoma, and cortical
vasculature in mice using dark-field PAM. (A) Top: a composite image of a melanoma acquired
at 764 nm and surrounding microvasculature acquired at 584 nm using a 50 MHz ultrasonic
detection frequency. Bottom: a B-scan image along the cut in the corresponding top figure. M,
melanoma. (B) Top: a cortical vasculature image obtained at 570 nm using a 20 MHz ultrasonic
detection frequency. Bottom: a B-scan image along the cut in the corresponding top figure.
SS, sagittal sinus; MCA, middle cerebral artery; CS, coronal suture. (Reprinted with permission
from ref 9. Copyright 2006 Nature, and from ref 27. Copyright 2009 American Institute of
Physics.)
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Figure 11.
In situ noninvasive PA images of internal organs in small and large animals using deep-
reflection mode PAM. PA images of liver (A) and kidney (B) in a rat. A PA images (C) of
intestine in a rabbit, and the corresponding invasive photograph (D) taken after the imaging.
AA, arcuate blood vessels; IB, interlobar blood vessels; IT, intestines; KN, kidney; LF,
lumbodorsal fascia; LV, liver; RV, blood vessels around ribs; SC, blood vessels in the spinal
cord; VC, vena cava inferior; BV, blood vessel; and IT, intestine. (Reprinted with permission
from ref 14. Copyright 2008 The American Association of Physicists in Medicine.)
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Figure 12.
Schematic of the OR-PAM. a, Condenser lens; b, pinhole; c, microscope objective; d, ultrasonic
transducer; e, correcting lens; f, isosceles prism; g, acoustic lens; h, silicon oil. (Reprinted with
permission from ref 12. Copyright 2008 The Optical Society of America.)
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Figure 13.
OR-PAM images of microvasculature in a nude mouse ear in vivo. (A) 2D OR-PAM MAP
image. (B), 3D visualization of the OR-PAM image. (C) photograph taken with transmission
optical microscopy. CL, capillary, and SG, sebaceous gland. (Reprinted with permission from
ref 12. Copyright 2008 The Optical Society of America.)
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Figure 14.
Spectra of two types of hemoglobin. Oxy-hemoglobin (HbO2) and deoxy-hemoglobin (HbR).
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Figure 15.
Static and dynamic SO2 imaging in rats’ skin. (A) Structural MAP image taken at 584 nm. (B)
Static SO2 mapping. Red, arterial blood; Blue, venous blood. (C) Structural MAP image taken
at 584 nm. (D) Static SO2 mapping under normoxia. Red, arterial blood; Blue, venous blood.
(E) Changes in SO2 from normoxia to hypoxia. (F) Changes in SO2 from normoxia to
hyperoxia. (G) Quantification of SO2 values in arteries and veins under three physiologic
conditions. (Reprinted with permission from ref 9. Copyright 2006 Nature, and from ref 16.
Copyright 2007 American Institute of Physics.)
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Figure 16.
In vivo noninvasive PA images of rat brain hemodynamic changes includingtotal hemoglobin
concentration (HbT) and oxygen saturation of hemoglobin (SO2). (A) and (B) Structural brain
images under normoxia at 584 and 600 nm laser light, respectively. (C) and (D) Images of
SO2 and HbT in the cortical venous area under normoxia. (E) The differential <SO2> (the
averaged SO2 level) image between normoxia and hyperoxia (hyperoxia - normoxia). (F) The
differential <SO2>image between normoxia and hypoxia (hypoxia - normoxia). (G) The
fractional change in HbT (<ΔHbT>/<HbT>) between hyperoxia and normoxia. (H) The
fractional change in HbT between hypoxia and normoxia. (I) Open-skull anatomical
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photograph taken after the PA imaging experiments. (Reprinted with permission from ref 15.
Copyright 2006 Society of Photo-Optical Instrumentation Engineers.)
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Figure 17.
Functional PA images of cerebral hemodynamic changes in response to whisker stimulations.
(A) and (B) Cerebral functional PA images in response to left and right whisker stimulation,
respectively. The map of increased PA signals (color) was superimposed on the gray-scale
structural PA image. (C) Open-skull photograph taken after the PA imaging experiments. B,
bregma; L, lambda; M, midline; A, activated regions. (D) Histology of normal lamina IV
cortical barrels (region A). (Reprinted with permission from ref 6. Copyright 2003 Nature.)
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Figure 18.
In vivo structural PA images of the mouse cortex vasculature. (A) Photograph of the scanned
region. (B) Noninvasive PA image of the mouse cortex vasculature. SS, sagittal sinus; CS,
coronal suture. (C) B-scan image obtained from scanning along the white dotted line in (B).
(Reprinted with permission from ref 41. Copyright 2009 Society of Photo-Optical
Instrumentation Engineers.)
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Figure 19.
Dynamic oxygenation profiles of five vessels. Profiles acquired through a hypoxic challenge
and shown in changes (%) of (A) ratiometric PA signals and (B) isosbestic PA signals. (C)
Close-up of the forward rising part of the dynamic vessel responses shown in A. (Reprinted
with permission from ref 41. Copyright 2009 Society of Photo-Optical Instrumentation
Engineers.)
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Figure 20.
In vivo PA images of tumor angiogenesis and the corresponding close-up images in a rat brain
acquired with (A) a 3.5-MHz ultrasonic transducer and (B) a 20-MHz ultrasonic transducer.
(C) Photograph of the rat brain LH, left cerebral hemisphere; V, blood vessels; E, eyes; T,
tumor. (Reprinted with permission from ref 13. Copyright 2005 The Optical Society of
America.)
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Figure 21.
In vivo functional PA images of U87 glioblastoma xenograft in a nude mouse brain. (A) SO2
image of the nude mouse brain (Red arrow: hypoxic region). (B) HbT image of the nude mouse
brain. (C) Comparison of normal and tumor vasculatures in SO2 (N = 3). (D) The SO2 versus
the relative HbT in normal and tumor vasculatures. (Reprinted with permission from ref 42.
Copyright 2008 The Institute of Electrical and Electronics Engineers, Inc.)
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Figure 22.
In vivo noninvasive OR-PAM monitoring of the healing process of a laser-induced
microvascular lesion. (A) Before laser treatment. (B) Immediately after laser treatment. (C)
On each of the subsequent 12 days. Left column, Photographs taken by a commercial
transmission-mode optical microscope; middle column, the front view of the 3D microvascular
morphology acquired by OR-PAM at 570 nm; right column, SO2 mapping of the laser-damaged
region overlaid with the morphological PA image. (Reprinted with permission from ref 50.
Copyright 2009 The American Association of Physicists in Medicine.)
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Figure 23.
Chemical structure of ICG.58
Kim et al. Page 54
Chem Rev. Author manuscript; available in PMC 2010 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 24.
In vivo noninvasive PA images of a rat brain using ICG-PEG as contrast agents. (A) and (B)
PA images obtained before and after the injection, respectively. MF, median fissure. (C)
Subtracted PA image between before and after the injection (C = B - A). (D) Open-skull
photograph after the PA imaging. (Reprinted with permission from ref 57. Copyright 2004 The
Optical Society of America.)
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Figure 25.
Two-dimensional cross-sectional PA images at various depths in biological tissues.
Photographs of (A) the cross section of chicken breast tissues where three pairs of tubes (whole
blood, ICG in water, and ICG in blood) are embedded and (B) the entire sample. Two-
dimensional PA images using a 2.25-MHz ultrasonic transducer at depths of (C) 1.3, (D) 2.6,
(E) 4.2, and (F) 5.2 cm. Two-dimensional PA images at a 5.2-cm depth acquired by (G) 3.5-
and (H) 5.0-MHz ultrasonic transducers. (Reprinted with permission from ref 56. Copyright
2005 The Optical Society of America.)
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Figure 26.
Chemical structure of IRDye800-NHS. 62
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Figure 27.
In vitro binding test of IRDye800-c(KRGDf) to integrin αvβ3 overexpressed U87 tumor cells.
(A) Fluorescence image of IRDye800-c(KRGDf) (6 µM) incubated U87 cells for 3 min. (B)
Fluorescence image of U87 cells incubated with an excess 1.2 mM of c(KRGDf) for 5 min and
then followed by a 6 µM of IRDye800-c(KRGDf) for 3 min. Red: IRDye800-c(KRGDf); green:
Sytox green-labeled cell nuclei. (Reprinted with permission from ref 42. Copyright 2008 The
Institute of Electrical and Electronics Engineers, Inc.)
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Figure 28.
In vivo molecular PA images of a nude mouse brain with a U87 glioblastoma xenograft using
IRDye800-c(KRGDf) as a molecular contrast agent. (A) A composite image of a fluorescence
image and white-light photograph of the mouse head acquired 20 h after the injection. (B) In
vivo molecular PA image of IRDye800-c(KRGDf). (C) A composite image of a segmented
molecular and structural image, both acquired with the PACT system. (Reprinted with
permission from ref 42. Copyright 2008 The Institute of Electrical and Electronics Engineers,
Inc.)
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Figure 29.
Chemical structure of methylene blue (MB).67
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Figure 30.
In vivo noninvasive PA images of the SLN in a rat. (A) Photograph with hair removed before
PA imaging. (B) Photograph with skin removed after PA imaging. (C) Control image before
the MB injection. (D) PA image immediately after the injection. (E) 52 min post-injection PA
image with the scan head repositioned. (F) PA image of the deeply positioned (~ 18 mm) SLN.
(Reprinted with permission from ref 65. Copyright 2008 Society of Photo-Optical
Instrumentation Engineers.)
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Figure 31.
Molar extinction profiles of oxyhemoglobin (HbO2), deoxyhemoglobin (Hb), and organic dyes
multiplied by nonradiative quantum yield.
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Figure 32.
(A)Transmission electron microscopy (TEM) image of 30-nm silver nanocubes synthesized
with a growth time of 20 h. (B) Scanning electron microscopy (SEM) image of gold nanocages
prepared with the silver cubes as a sacrificial template. The inset shows a TEM image of the
same sample. (C) Extinction spectra taken from aqueous suspensions of the silver nanocubes
and the corresponding gold nanocages. (D) Spectra calculated using the DDA method for a
gold nanocage with the dimensions shown in the inset (extinction = absorption + scattering).
(Reprinted with permission from refs 91,104. Copyright 2005 American Chemical Society.)
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Figure 33.
(A) Schematic illustration of the formation of immuno gold nanocages. (B) SEM image of a
typical SK-BR-3 cancer cell whose surface was directly targeted by immuno gold nanocages
of 36 nm in size. The inset shows an image at higher magnification (scale bar = 100 nm). (C)
SEM image of a typical SK-BR-3 cell that had been incubated with PEGylated nanocages (i.e.,
no specific targeting), showing essentially no nanocages on the surface. (Reprinted with
permission from refs 91,104. Copyright 2005 American Chemical Society.)
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Figure 34.
In vivo noninvasive PA images of the cerebral cortex acquired (A) before the injection, and
(B) ~2 h after the final of PEGylated nanocages via tail vein. (C) A differential image (34B
subtracted from 34A). (D) An open-skull photograph of the rat’s cerebral cortex. (E)
Quantification of the PA signal enhancement after the injection as a function of time. (Reprinted
with permission from ref 90. Copyright 2007 American Chemical Society.)
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Figure 35.
Noninvasive in vivo PA images of the SLN in a rat. (A) Photograph of axillary region with hair
removed before the injection of gold nanocages. (B) Photograph with skin removed after the
PA images had been captured. PA images acquired before (C) and after (D–H) the nanocage
injection: (D) 5 min (SLN started to appear), (E) 59 min, (F) 140 min, (G) 194 min. (H) The
increase of PA signal in the SLN as a function of time. BV, blood vessels; SLN, sentinel lymph
node. (Reprinted with permission from ref 89. Copyright 2009 American Chemical Society.)
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Figure 36.
In vivo noninvasive PA images of the cerebral cortex acquired (A) before the injection, and
(B) ~20 min after the final injection of PEGylated nanoshells via tail vein. (C) A differential
image (36B subtracted from36A). (D) An open-skull photograph of the rat’s cerebral cortex
showing that the PA images agreed with the location of blood vessels. (E) Quantification of
the PA signal enhancement after the injection as a function of time. (Reprinted with permission
from ref 82. Copyright 2004 American Chemical Society.)
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Figure 37.
In vivo noninvasive PA images of nanoshell extravasation in a tumor. (A) Control image before
the injection of nanoshells. (B), (C), and (D) PA images of accumulation of nanoshells at 1.4,
3, and 5.8 h post-injection, respectively. (E) Averaged PA signals as a function of time. Line
with circles: vessel regions; dashed line with squares: tumor foci. (Reprinted with permission
from ref 105. Copyright 2009 Society of Photo-Optical Instrumentation Engineers.)
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Figure 38.
(A) Absorbance spectra of control, targeted and non-targeted phantoms. (B), (D), and (F) PA
images (λ = 532 nm) of control, targeted, and non-targeted phantoms, respectively. (C), (E),
and (G) PA images (λ = 680 nm) of control, targeted, and non-targeted phantoms, respectively.
(Reprinted with permission from ref 106. Copyright 2007 The Optical Society of America.)
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Figure 39.
PA images of (A) stimulated and (B) unstimulated ECs binding with anti-ICAM-1 conjugated
gold nanorods, and (C) stimulated and (D) unstimulated ECs binding with blank gold nanorods.
(Reprinted with permission from ref 112. Copyright 2007 American Institute of Physics.)
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Figure 40.
(A) In vivo noninvasive PA A-line image of a nude mouse after the injection of gold nanorods
(25 µL at a concentration of 1.25 pM) or PBS (25 µL). The x-axis of (A) is the time of arrival
of ultrasound. A typical PA image of a nude mouse before (B) and after (C) subcutaneous
injection of 100 µL of gold nanorods at a concentration of 7.5 × 1010 nanorods/mL in the
abdominal area. Injected nanoparticles were brightly visible in the PA image (C). (Reprinted
with permission from ref 111. Copyright 2007 American Chemical Society.)
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Figure 41.
In vivo noninvasive molecular PA Images of Cal27 tumors before and after the injection of
AuNR1000-EGFR and AuNR1000. Ellipses indicate the tumor regions. (A) Time-course
composite of US and PA images before and after AuNR1000-EGFR injection. US image in
gray scale and PA image in red pseudo-color. (B) Time-course composite of US and PA images
before and after AuNR1000 injection. (C) Averaged image intensities within the tumor region
as a function of time after injections of AuNR1000-EGFR (blue solid line) and AuNR1000 (red
dashed line). (Reprinted with permission from ref 18. Copyright 2008 The Optical Society of
America.)
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Figure 42.
In vivo noninvasive molecular PA Images of OECM1 tumors before and after the injection of
AuNR785-HER2 and AuNR785. Ellipses indicate the tumor regions. (A) Time-course
composite of US and PA images before and after AuNR785-HER2 injection. US image in gray
scale and PA image in red pseudo-color. (B) Time-course composite of US and PA images
before and after AuNR785 injection. (C) Averaged image intensities within the tumor region
as a function of time after injections of AuNR785-HER2 (blue solid line) and AuNR785 (red
dashed line). (Reprinted with permission from ref 18. Copyright 2008 The Optical Society of
America.)
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Figure 43.
In vivo noninvasive PA images of the axilla, showing the vasculature and sentinel lymph node.
(A) Photograph of the axilla with hair removed before imaging. (B) Photograph of the axilla
with tissue removed. SLN is indicated by an arrow. Insets are a top view and a bottom view
of the excised SLN, respectively. (C) B-scan acquired along the dotted line in (G). (D) PA
image taken before the injection as a control. (E) PA image at 1.5 h post-injection. (F) PA
image at 19 h injection. (G). PA image acquired at 46 h post-injection. (Reprinted with
permission from ref 113. Copyright 2009 Elsevier.)
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Figure 44.
(A) Illustration of plain-SWNT and SWNT–RGD. (B) Photoacoustic spectra of plain-SWNT
and SWNT-RGD overlaid on optical spectra of oxyhemoglobin (HbO2) and deoxyhemoblobin
(Hb). (Reprinted with permission from ref 19. Copyright 2008 Nature.)
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Figure 45.
In vivo noninvasive molecular PA images of U87MG tumors before and after the injection of
SWNTs-RGD and plain-SWNTs. The structural ultrasound image is shown in gray scale and
the PA image is shown in green scale. (A) Time-course composite of US and PA images before
and after SWNT-RGD and plain-SWNT. Subtraction image: PA image at 4 h post-injection –
control PA image. White arrows in the left column indicate the PA signals in the mouse injected
with plain-SWNT. (B) Averaged image intensities within the tumor region as a function of
time after injection of SWNTs-RGD (n = 4, red solid line) and plain-SWNTs (n = 4, blue solid
line). (Reprinted with permission from ref 19. Copyright 2008 Nature.)
Kim et al. Page 76
Chem Rev. Author manuscript; available in PMC 2010 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 46.
In vivo noninvasive PA images of the axilla, showing the vasculature and sentinel lymph node.
(A) The control PA image taken before the injection. (B) PA image taken immediate after the
injection. (C) – (E) PA images at 30, 55, and 85 min post-injection, respectively. (F) The uptake
kinetics of the SWNTs. (Reprinted with permission from ref 116. Copyright 2009 Institute of
Physics.)
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Figure 47.
Preparation of gold nanobeacons from octanethiol-functionalized gold nanoparticles (AuNPs).
(Reprinted with permission from ref 124. Copyright 2009 Wiley-VCH Verlag GmbH & Co.)
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Figure 48.
In vivo noninvasive PA vascular structural images of a rat. (A) Control PA image acquired
before GNB injection. (B) PA image acquired 156 min after injection of GNBs. (C)
Pharmacokinetics of GNBs in a blood vessel after injection (blue arrow: point of GNBs
injection). (Reprinted with permission from ref 124. Copyright 2009 Wiley InterScience.)
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Figure 49.
PA image of nanowonton phantom. (A) Optical absorbance of nanowontons. (B) PA image of
4 absorbing objects containing nanowonton concentrations of 100 , 50, 25, and 13 pM,
respectively, for objects A, B, C, and D. (Reprinted with permission from ref 125. Copyright
2009 National Academy of Sciences.)
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Figure 50.
Optical spectra of the blue product, oxyhemoglobin (HbO2), and deoxyhemoglobin (Hb).
(Reprinted with permission from ref 127. Copyright 2007 Society of Photo-Optical
Instrumentation Engineers.)
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Figure 51.
In vivo noninvasive PA mages of lacZ-marked tumor. (A) PA image acquired at 635 nm
showing the tumor morphology after X-gal staining. (B) PA image acquired at 584 nm showing
microvasculature. (C) A composite image of the surrounding vasculature (B) and the primary
tumor (C). (Reprinted with permission from ref 128. Copyright 2008 World Scientific.)
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Figure 52.
Three-dimensional in vivo PA images of the brain of an adult mCherry-expressing transgenic
zebrafish. (A) Five transverse PA images taken at 585 nm. (B) A PA image and (C) its
corresponding histological section. DM, dorsal fin musculature; B, hindbrain; N, lateral line
nerve; O, operculum; S, skull bones; P, pharynx; H, heart; HM, hypobranchial musculature.
(D) PA image of the brain with mCherry expression. (E) Corresponding fluorescent histology
of a dissected brain. (Reprinted with permission from ref 129. Copyright 2009 Nature.)
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Table 1
Summaries of chemical and optical properties of organic dyes.
Dyes Indocyanine green58 IRDye800-NHS62 Methylene blue67,74
Molecular weight [g/mol] 775 1165 320
Molecular formula C43H47N2NaO6S2 C50H54N3Na3O17S4 C16H18N3ClS
Peak molar extinction coefficient
[cm−1M−1] 1.5 × 10
5 2.7 × 105 7.4 × 104
Peak absorption wavelength [nm] 790 795 667
Fluorescence quantum yield [%] 10% in DMSO< 1% in water 15% 0.04%
Peak molar extinction coefficient
× nonradiative quantum yield
[cm−1M−1]
1.4 × 105 2.3 × 105 7.1 × 104
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Table 2
Comparison of the optical cross-sections of Au-based nanostructures obtained experimentally by photoacoustic
imaging and theoretical calculation, respectively. (Reprinted with permission from ref 126. Copyright 2009
American Chemical Society.)
Cross-section (10−15 m2)
Extinction Absorption σa /σe
(σe) (σa)
Nanocages Experimental 7.26± 0.06 5.96 ± 0.25 0.82 ± 0.04
(45.0 nm) Calculated 19.88 16.26 0.82
Nanocages Experimental 2.99 ± 0.04 3.05 ± 0.12 1 ± 0.04
(32.0 nm) Calculated 6.39 6.02 0.94
Nanorods Experimental 2.16 ± 0.02 1.87 ± 0.23 0.87 ± 0.11
(44.0 × 19.8 nm2) Calculated 2.15 1.83 0.85
Nanospheres Experimental 145 ±14.76 - -
(150 nm) Calculated 99.96 5.73 0.056
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